ArticleRSC advances2018

SKLB023 as an iNOS inhibitor alleviated liver fibrosis by inhibiting the TGF-beta/Smad signaling pathway.

Jinhang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.